• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Maxcyte Inc (NQ: MXCT )

    3.860 +0.100 (+2.66%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Maxcyte Inc

    < Previous 1 2 Next >
    MaxCyte to Participate in Two Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Cynthia Collins to its Board of Directors
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
    Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
    Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
    Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
    Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
    Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer... 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
    Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. 
    From MaxCyte, Inc; Lion TCR
    Via GlobeNewswire
    MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
    MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Two Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Baird Global Healthcare Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
    Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative... 
    From MaxCyte, Inc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.